Background: AEs are observed in patients receiving monotherapy with tremelimumab, durvalumab, ipilimumab, or nivolumab, as well as in those receiving combination therapy with tremelimumab plus durvalumab or ipilimumab plus nivolumab
Ueda S, Yamagishi SI, Matsumoto Y, Fukami K, Okuda S (2007) Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease
doi: 10.1016/bs.acc.2020.01.001 107 BuckleyDNLewingerJPGoodenGSpillmanMNeumanMGuoXMet al
A safety analysis by Vukojevic et al
This study examines how spatial configurations perpetuate exclusion and proposes design interventions to balance visibility and privacy, ensuring equitable access to health-promoting environments